Sharekhan

Sanofi Consumer Healthcare India Ltd

Mon 1/12/2025,15:54:21 | NSE : SANOFICONR

₹ 4616.20-43.50 (-0.93%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 4699.70

Previous Close

₹ 4659.70

Volume

2834

Mkt Cap ( Rs. Cr)

₹10631.40

High

₹ 4699.70

Low

₹ 4606.00

52 Week High

₹ 5894.50

52 Week Low

₹ 4537.45

Book Value Per Share

₹ 118.55

Dividend Yield

0.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Sanofi Consumer Healthcare India Ltd

Your Vote -

Buy

81.82%

Hold

0.00%

Sell

18.18%

81.82%

11 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

4616.20

39

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

39

Option Chain

Analyzes market sentiment, predicts Sanofi Consumer Healthcare India Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Sanofi Consumer Heal - Copy of Newspaper Publication

    14 Nov 2025, 7:45PM Sanofi Consumer Healthcare India Limited has informed the Exchange about Copy of Newspaper Publication
  • Sanofi Consumer Heal - Press Release

    12 Nov 2025, 8:58PM Sanofi Consumer Healthcare India Limited has informed the Exchange regarding a press release dated November 12, 2025, titled ""Press Release"".
  • Sanofi Consumer Heal - Outcome of Board Meeting

    12 Nov 2025, 8:54PM Sanofi Consumer Healthcare India Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
  • Sanofi Consumer Heal Q3 net profit up 39.78% at Rs 62.90 cr

    12 Nov 2025, 8:44PM The company reported standalone net profit of Rs 62.90 crore for the quarter ended September 30, 2025 as compared to Rs 45.00 crore in the same period
  • Sanofi Consumer Heal - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    12 Nov 2025, 8:43PM Press release in reference to financial results for the quarter and nine months ended September 30, 2025.
  • Sanofi Consumer Heal - Results-Financial Results For September 30, 2025

    12 Nov 2025, 8:38PM Results for the quarter and nine months ended September 30, 2025
  • Sanofi Consumer Heal - Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday, 12Th November 2025

    12 Nov 2025, 8:31PM We wish to inform you that the Board of Directors at its meeting held today i.e., Wednesday, 12th November 2025, inter-alia considered and approved th
  • Sanofi Consumer Heal - Board Meeting Intimation for Board Meeting Intimation For Consideration And Approval Of Unaudited Fina

    5 Nov 2025, 6:54PM Sanofi Consumer Healthcare India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 ,inter alia,
  • Sanofi Consumer Heal - Shareholders meeting

    30 Oct 2025, 5:36PM Sanofi Consumer Healthcare India Limited has submitted the Exchange a copy Scrutinizers report along with Voting Results for the Postal Ballot Notice
  • Sanofi Consumer Heal - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

    30 Oct 2025, 5:25PM Please find enclosed Voting Results for the Postal Ballot Notice dated 4th August 2025
  • Sanofi Consumer Heal - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report

    30 Oct 2025, 5:22PM Please find enclosed Scrutinizer's Report issued by M/s. MMJB & Associates LLP w.r.t. Postal Ballot Notice dated 4th August 2025
  • Sanofi Consumer Heal - Appointment

    16 Oct 2025, 8:16PM Sanofi Consumer Healthcare India Limited has informed the Exchange regarding Appointment of Mr. Richard D'souza as Chief Financial Officer of the comp
  • Sanofi Consumer Heal - Announcement under Regulation 30 (LODR)-Change in Management

    16 Oct 2025, 8:16PM Appointment of Mr. Richard D'souza as Chief Financial Officer of the Company w.e.f. 16th October 2025
  • Sanofi Consumer Heal has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2025

    16 Oct 2025, 1:30PM As of September 2025, 71.27% is owned by Foreign Promoters and 28.73% by Public. <p align=justify> Institutional holds 20.15% (Insurance Companies 3.8
  • Sanofi Consumer Heal - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    10 Oct 2025, 4:11PM Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2025 is enclosed.
  • Sanofi Consumer Heal - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    10 Oct 2025, 4:07PM Sanofi Consumer Healthcare India Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for
  • Sanofi Consumer Heal - Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)

    10 Oct 2025, 3:55PM Resignation of Mr. Narahari Naidu as Chief Financial Officer of the Company
  • Sanofi Consumer Heal - Resignation

    10 Oct 2025, 3:54PM Sanofi Consumer Healthcare India Limited has informed the Exchange regarding Resignation of Mr Narahari Naidu as Chief Financial Officer of the compan
  • Sanofi Consumer Heal - Copy of Newspaper Publication

    30 Sep 2025, 1:33PM Sanofi Consumer Healthcare India Limited has informed the Exchange about Copy of Newspaper Publication of Postal Ballot Notice
  • Sanofi Consumer Heal - Shareholders meeting

    29 Sep 2025, 7:56PM Sanofi Consumer Healthcare India Limited has informed the Exchange regarding Notice of Postal Ballot
  • Sanofi Consumer Heal - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    29 Sep 2025, 7:56PM Intimation of dispatch of Postal Ballot Notice to the Shareholders
  • Sanofi Consumer Heal - Trading Window

    27 Sep 2025, 12:20PM Sanofi Consumer Healthcare India Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Tradi

Key fundamentals

Evaluate the intrinsic value of Sanofi Consumer Healthcare India Ltd stock 

Name December-24 March-24 December-23
Assets 1.7 1.7 1.7
Liabilities 1.7 1.7 1.7
Equity 2 2 2
Gross Profit 0 0 -0.3
Net Profit 0 0 -0.3
Cash From Operating Activities -0.4 -0.4 -0.4
NPM(%) 0 0 29.69
Revenue 0 0 0
Expenses 0 0 0.3
ROE(%) 0 0 -0.1

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
17 Apr 2025 55 550 0 4756.85

Peers

Other companies within the same industry or sector that are comparable to Sanofi Consumer Healthcare India Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Sharda Cropchem Ltd 871.20 0.99 17.40 41701.27 337.37 1.03
Amines and Plasticizers Ltd 194.88 -0.92 29.66 25431.07 372.61 0.26
Indogulf Cropsciences Ltd 86.91 -1.65 10.37 10870.70 49.78 0.00
Grauer and Weil (India) Ltd 115.60 0.00 34.71 209573.83 346.70 0.43

Company Info

The Company was incorporated as a public limited company under the Companies Act, 2013, pursuant to a certificate of incorporation dated May 10, 2023, issued by the Registrar of Companies, Central Registration Centre. Major Events and Milestones:2023 Incorporation of the Company 2024 Demerger, transfer and vesting of the Demerged Undertaking from Sanofi India Limited into the  Company on a going concern basis pursuant to the Scheme  2020 -Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030. 2021 -Sanofi completed acquisition of Kadmon. -Sanofi completed acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics. -Sanofi launched its new global employee share ownership plan. -Sanofi established three-year collaboration with Stanford Medicine to accelerate immunology research. 2022 -Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology. -Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine. -Sanofi launches its first Digital Accelerator fueled by new talent and focused on growth. -Sanofi recognized by S&P as one of the most sustainability- committed companies. -Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board. 2023 -Sanofi's Consumer Healthcare Unit launches the Shared Care Collective, an advisory group working to advance sustainability. -Sanofi completes acquisition of Qunol. -Sanofi completes acquisition of Provention Bio, Inc. - Sanofi Consumer Healthcare launches new portal to unlock science and solve key challenges in self-care. 2024 -Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline.

The Company was incorporated as a public limited company under the Companies Act, 2013, pursuant to a certificate of incorporation dated May 10, 2023, issued by the Registrar of Companies, Central Registration Centre. Major Events and Milestones:2023 Incorporation of the Company 2024 Demerger, transfer and vesting of the Demerged Undertaking from Sanofi India Limited into the  Company on a going concern basis pursuant to the Scheme  2020 -Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030. 2021 -Sanofi completed acquisition of Kadmon. -Sanofi completed acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics. -Sanofi launched its new global employee share ownership plan. -Sanofi established three-year collaboration with Stanford Medicine to accelerate immunology research. 2022 -Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology. -Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine. -Sanofi launches its first Digital Accelerator fueled by new talent and focused on growth. -Sanofi recognized by S&P as one of the most sustainability- committed companies. -Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board. 2023 -Sanofi's Consumer Healthcare Unit launches the Shared Care Collective, an advisory group working to advance sustainability. -Sanofi completes acquisition of Qunol. -Sanofi completes acquisition of Provention Bio, Inc. - Sanofi Consumer Healthcare launches new portal to unlock science and solve key challenges in self-care. 2024 -Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline.

Read More

Parent Organisation

Sanofi Consumer Healthcare India Ltd.

Founded

10/05/2023

Managing Director

Mr.Himanshu Bakshi

NSE Symbol

SANOFICONREQ

FAQ

The current price of Sanofi Consumer Healthcare India Ltd is ₹ 4616.20.

The 52-week high for Sanofi Consumer Healthcare India Ltd is ₹ 4699.70 and the 52-week low is ₹ 4606.00.

The market capitalization of Sanofi Consumer Healthcare India Ltd is currently ₹ 10631.40. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Sanofi Consumer Healthcare India Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Sanofi Consumer Healthcare India Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Sanofi Consumer Healthcare India Ltd shares.

The CEO of Sanofi Consumer Healthcare India Ltd is Mr.Himanshu Bakshi, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT